Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SHE:300534)
China · Delayed Price · Currency is CNY 12.58
-0.05 (-0.40%)
Sep 30, 2026, 3:04 PM CST
SHE:300534 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,816 | 2,876 | 2,639 | 2,994 | 2,691 | 4,465 | |
Market Cap Growth | 30.09% | 8.97% | -11.85% | 11.27% | -39.74% | 154.23% |
Enterprise Value | 3,853 | 2,895 | 2,506 | 2,942 | 2,608 | 4,404 |
Last Close Price | 12.58 | 9.46 | 8.64 | 9.76 | 8.77 | 14.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 110.44 | 65.43 | 107.82 | 48.57 | 69.37 | - |
PS Ratio | 5.17 | 3.24 | 2.53 | 2.77 | 3.37 | 15.51 |
PB Ratio | 4.78 | 3.68 | 3.57 | 4.21 | 3.05 | 6.09 |
P/TBV Ratio | 6.01 | 4.59 | 4.45 | 5.37 | 3.57 | 6.81 |
P/FCF Ratio | 332.05 | - | 19.23 | - | 11.12 | 88.04 |
P/OCF Ratio | 91.41 | - | 12.28 | 31.02 | 10.06 | 87.32 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.22 | 3.26 | 2.40 | 2.72 | 3.26 | 15.30 |
EV/EBITDA Ratio | 35.64 | 22.41 | 18.63 | 26.34 | 31.31 | 332.41 |
EV/EBIT Ratio | 61.70 | 33.09 | 26.10 | 35.96 | 46.31 | - |
EV/FCF Ratio | 335.30 | - | 18.26 | - | 10.78 | 86.84 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.16 | 0.17 | 0.16 | 0.20 | - | - |
Debt / EBITDA Ratio | 1.14 | 1.01 | 0.85 | 1.29 | - | - |
Debt / FCF Ratio | 10.76 | - | 0.84 | - | - | - |
Net Debt / Equity Ratio | -0.06 | -0.14 | -0.26 | -0.20 | -0.42 | -0.13 |
Net Debt / EBITDA Ratio | -0.43 | -0.84 | -1.45 | -1.29 | -4.43 | -7.48 |
Net Debt / FCF Ratio | -3.97 | 2.18 | -1.42 | 4.84 | -1.53 | -1.95 |
Asset Turnover | 0.55 | 0.63 | 0.75 | 0.81 | 0.75 | 0.34 |
Inventory Turnover | 2.03 | 2.44 | 2.73 | 4.22 | 4.83 | 4.02 |
Quick Ratio | 1.20 | 1.11 | 1.03 | 1.21 | 1.50 | 3.59 |
Current Ratio | 1.65 | 1.43 | 1.32 | 1.48 | 1.79 | 4.52 |
Return on Equity (ROE) | 7.05% | 8.60% | 6.90% | 10.52% | 6.02% | -0.86% |
Return on Assets (ROA) | 2.90% | 3.85% | 4.31% | 3.85% | 3.29% | -0.69% |
Return on Invested Capital (ROIC) | 6.21% | 11.58% | 8.50% | 13.08% | 7.22% | -1.41% |
Return on Capital Employed (ROCE) | 6.50% | 9.30% | 10.60% | 9.10% | 6.20% | -1.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.91% | 1.53% | 0.93% | 2.06% | 1.44% | -0.20% |
FCF Yield | 0.30% | -1.74% | 5.20% | -1.00% | 9.00% | 1.14% |
Dividend Yield | 0.32% | 0.42% | 0.46% | 0.21% | - | - |
Payout Ratio | 42.88% | 33.75% | 63.61% | 6.19% | 1.28% | - |
Buyback Yield / Dilution | -0.04% | -0.01% | 0.03% | -0.05% | 0.10% | 0.54% |
Total Shareholder Return | 0.28% | 0.42% | 0.49% | 0.16% | 0.10% | 0.54% |